Johnson & Johnson's "New Era" of Growth: Why the Market Underestimates Its Innovative Pipeline

Related Articles

Why is Johnson & Johnson Selling its Orthopedics Unit

6 months ago

Is Johnson & Johnson's $1 Billion Cell Therapy Investment a Game Changer

6 months ago

What's Driving Johnson Controls' Recent Momentum Ahead of Q2 Earnings

4 months ago

Is the Defense Sector Entering a New Era of Growth

6 months ago

Category

You may also like

Stock News•1 week ago

J&J's Strong Pipeline Momentum Offers Multiple Growth Catalysts Ahead

Johnson & Johnson's pipeline momentum is expected to support growth through 2026 and beyond, driven by new launches, late-stage data, and approvals. The company's diversified portfolio could provide m...

JNJ

Share

Stock News•1 week ago

Johnson & Johnson Just Sent Shareholders an Important 11-Word Message About Its Future

Johnson & Johnson signaled that new drugs could offset declining sales from patent-protection losses, an 11-word message to shareholders about its future growth strategy.

JNJ

Share

Stock News•1 months ago

J&J's MedTech Performance Slows in Q2: Will Sales Improve in H2?

J&J's MedTech growth slowed in Q2, with Cardiovascular lagging. New product launches and stronger Vision, Surgery and Orthopedics could lift H2 sales.

JNJ

Share